Merz Pharma Gmbh & Co Kgaa

Ipsen Bioinnovation Limited

Syntaxin Limited

Tanja Weil

Aleksandrs Gutcaits

Andreas Rummel

Ivars Kalvinsh

Wojciech Danysz

Valerjans Kauss

Markus Henrich

Christopher Graham Raphael Parsons

Claudia Jatzke

Jens Nagel

Aigars Jirgensons

Maksims Vanejevs

Andrzej Dekundy

Mirko Hechenberger

Juris Fotins

Ronalds Zemribo

Ieva Jaunzeme

Aleksandra Gutcaits

The present invention relates to a transport protein which can be obtained by modifying the heavy chain of the neurotoxin formed bywherein (i) the protein binds specifically to nerve cells with a higher or lower affinity as the native neurotoxin; (ii) the protein has an increased or reduced neurotoxicity compared to the native neurotoxin, the neurotoxicity being preferably determined in the hemidiaphragm assay; and/or (iii) the protein comprises a lower affinity against neutralizing antibodies compared to the native neurotoxin. The invention also relates to methods for producing the same and the use thereof in cosmetic and pharmaceutical compositions.

Carrier for targeting nerve cells

The present invention relates to a transport protein which can be obtained by modifying the heavy chain of the neurotoxin formed bywherein (i) the protein binds specifically to nerve cells with a higher or lower affinity as the native neurotoxin; (ii) the protein has an increased or reduced neurotoxicity compared to the native neurotoxin, the neurotoxicity being preferably determined in the hemidiaphragma assay; and/or (iii) the protein comprises a lower affinity against neutralizing antibodies compared to the native neurotoxin. The invention also relates to methods for producing the same and the use thereof in cosmetic and pharmaceutical compositions.

Substituted pyrazolopyrimidine derivatives of formula (I) wherein

Substituted pyrazolo[1,5-A]pyrimidines as metabotropic glutamate receptor modulators

The invention relates to pyrazolopyrimidine derivatives of formula (I) wherein

Substituted pyrazolo[1,5-a]pyrimidines as metabotropic glutamate receptor modulators

The invention relates to tetrahydroquinolinone derivatives as well as their pharmaceutically acceptable salts. The invention further relates to a process for the preparation of such compounds. The compounds of the invention are group I mGluR antagonists and are therefore useful for the control and prevention of acute and/or chronic neurological disorders.

Tetrahydroquinolinones and their use as antagonists of metabotropic glutamate receptors

The invention relates to ethynyl-substituted tetrahydroquinolinone derivatives as well as their pharmaceutically acceptable salts. The invention further relates to a process for the preparation of such compounds. The compounds of the invention are group I mGluR modulators and are therefore useful for the control and prevention of acute and/or chronic neurological disorders.

Tetrahydroquinolones and their use as modulators of metabotropic glutamate receptors

Growing community of inventors

Frankfurt am Main, Germany

Tanja Weil